Crescent Biopharma, Inc.

US$13.54As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:CBIOHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR —
Div yield —
ROE —
Biotechnology
Beta (5Y) —
PE TTM —
TSR TTM 6.20%
Mkt cap US$579.5M
ROIC —
SE Grade™
Value
Quality
Moat
Consensus
Reference
$13
(2.74%)
111.82%
Sell 4|7|4|8|11
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.16
0.18
0.17
0.18
11.55%
22.09%
10.86%
20.73%
Revenue$M
67.57
68.85
71.27
69.16
9.04%
7.32%
5.43%
2.94%
Peers (US$579.5M)
Cap (US$)
PE
595.5M
—
Capital
TTM
5Y
10Y
Leveragex
2.775
(0.056)
(0.046)
EBIT/Intx
3.326
0.069
0.087
Own earn%
15.77
46.93
55.25
Sh yield%
16.09
44.39
45.16
Owners
Insiders/Inst%
11.08
79.71
Short interest%
2.76
SBC / revenue%
1.31
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
8
Op margin range%
0–8
$1 testx
36.9
Incr. ROIC%
15